In a preclinical melanoma model, tumor-intrinsic β-catenin activation was shown to impair the infiltration of T cells and CD103+ DCs, which is related to reduced CCL4 secretion from tumors and leads to therapeutic resistance to the combined PD-1 and CTLA-4 blockade. Here, PDCD1 is linked to neoplasm.